Is Femasys Inc. (FEMY) a Buy, Sell, or Hold?
NASDAQ : FEMY
Femasys Inc.
$3.57 USD
-$0.03 (-0.83%)
- Volume
- 10.76K
- Average Volume
- 62.04K
- Market Capitalization
- $10.78M
- P/E Ratio
- -0.56
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $22.20
- Year Low
- $3.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.91
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Kathy Lee-Sepsick |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Current Symbol | FEMY |
| CUSIP | 31447E204 |
| CIK | 0001339005 |
| Web | https://www.femasys.com |
| Phone | 770 500 3910 |
| Currency | USD |
| Employees | 54 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.65 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.91 |
| Quick Ratio | 1.98 |
| Cash Ratio | 1.71 |
Sales & Book Value
| Annual Sales | $2.29M |
| Price / Sales | 4.54 |
| Cash Flow | -5.59 |
| Price / Cash Flow | -0.58 |
| Price / Book | 1.63 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$9.4 |
| Trailing P/E Ratio | -0.56 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | -$18.63M |
| Net Margin | -521.78% |
| Pretax Margin | -499.78% |
| Return on Equity | -258.08% |
| Return on Assets | -75.19% |
Financials Score
| AltmanZ Score | -12.86 |
| Piotroski Score | 2.00 |
| Working Capital | 9.19M |
| Total Assets | 16.5M |
| Ebit | -10.27M |
| Market Cap | 10.51M |
| Total Liabilities | 9.21M |
Poll Results
About Femasys Inc. (NASDAQ:FEMY) Stock
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare pr ... ofessionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Femasys Regains Compliance with Nasdaq Listing Requirements
2026-06-24 09:00:00
ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today that it received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) confirming the Company has regained compliance with Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing and that the matter is now closed.
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
2026-05-13 09:00:00
-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- -- New catheter complements FemVue® and supports streamlined in-office fertility evaluation --
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
2026-05-08 16:05:00
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- -- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices --
2026-05-05 09:00:00
-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the first revenue-generating commercial use of its fertility portfolio in the OBGYN setting, led by FemaSeed as a first-line infertility treatment. The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women's primary physician, where earlier intervention can improve access and outcomes.
Financial Analysis: CRISPR Therapeutics (NASDAQ:CRSP) and Femasys (NASDAQ:FEMY)
2026-04-17 01:29:05
CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) and Femasys (NASDAQ: FEMY - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends. Earnings and Valuation This table compares CRISPR Therapeutics and
Frequently Asked Questions
-
What is the current Femasys Inc. (FEMY) stock price?
-
Femasys Inc.(NASDAQ:FEMY) stock price is $3.57 in the last trading session. During the trading session, FEMY stock reached the peak price of $22.2 while $3.39 was the lowest point it dropped to. The percentage change in FEMY stock occurred in the recent session was --0.83% while the dollar amount for the price change in FEMY stock was -$0.03.
-
FEMY's industry and sector of operation?
-
The NASDAQ listed FEMY is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of FEMY?
-
James H. Liu | Chief Medical Officer
Jeffrey Marcus | Chief Medical Advisor
Benjamin Dings | Vice President of Sales
Dov Elefant | Chief Financial Officer
Jeremy Alexander Sipos | Chief Technology Officer -
How many employees does FEMY have?
-
Number of FEMY employees currently stands at 54. FEMY operates from 3950 Johns Creek Court, Suwanee, GA 30024, US.
-
Link for FEMY official website?
-
Official Website of FEMY is: https://www.femasys.com
-
How do I contact FEMY?
-
FEMY could be contacted at phone #770 500 3910 and can also be accessed through its website. FEMY operates from 3950 Johns Creek Court, Suwanee, GA 30024, US.
-
How many shares of FEMY are traded daily?
-
The average number of FEMY shares traded daily for last 3 months was 62.04K.
-
What is the market cap of FEMY currently?
-
The market value of FEMY currently stands at $10.78M with its latest stock price at $3.57